Structure Therapeutics Inc. (GPCR) shares are falling more than 51 percent on Monday morning trade, on reports that its weight loss and diabetes drug GSBR-1290's performance was weaker than its rival Eli Lilly's orforglipron at eight weeks.
GSBR -1290 demonstrated a clinically meaningful decrease in weight, or 4.74 percent higher than placebo.
Currently, GPCR shares are at $28.16, down 52.40 percent from the previous close of $59.16 on a volume of 2,354,862.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.